Biologic therapies for advanced pancreatic cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 8, 2008, Pages 1331-1338

  He, Aiwu Ruth ^a   Lindenberg, Andreas Peter ^b   Marshall, John Lindsay ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Biologic therapy; EGF receptor; K RAS; Pancreatic cancer; VEGF

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CGP 69846A; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; LONAFARNIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OXALIPLATIN; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; TIPIFARNIB; VASCULOTROPIN INHIBITOR; VATALANIB; EPIDERMAL GROWTH FACTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; REVIEW; SKIN TOXICITY; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 54549111166     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.8.1331     Document Type: Review

References (56)

1. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann. Surg. 211(4), 447-458 (1990).
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. Surg. 165(1), 68-72; discussion 72-73 (1993).
3. Tsao JI, Rossi RL, Lowell JA. Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation? Arch. Surg. 129(4), 405-412 (1994).
4. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann. Surg. 221(6), 721-731; discussion 731-733 (1995).
5. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997).
6. Cunningham SC, Cusnir M, Burdick RK, Van Echo DA, Moesinger R. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease. Clin. Adv. Hematol. Oncol. 1(12), 741-742; discussion 743 (2003).
7. Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24(24), 3946-3952 (2006).
8. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23(15), 3509-3516 (2005).
9. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22(18), 3776-3783 (2004).
10. Oettle H, Richards D, Ramanathan RK et al. A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 16(10), 1639-1645 (2005).
11. Büchler P, Reber HA, Roth MM, Shiroishi M, Friess H, Hines OJ. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia 9(2), 119-127 (2007).
12. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. Am. J. Pathol. 145(6), 1547-1550 (1994).
13. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57(9), 1731-1734 (1997).
14. Hudes G, Schol J, Baab J et al. Phase I clinical and pharmacokinetic trial of e farnesyltransferase inhibitor R115777 on a 21-day dosing schedule (meeting abstract). Presented at: 35th ASCO Annual Meeting. GA, USA, 15-18 May 1999.
15. Cohen SJ, Ho L, Ranganathan S et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21(7), 1301-1306 (2003).
16. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22(8), 1430-1438 (2004).
17. End DW, Smets G, Todd AV et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61(1), 131-137 (2001).
18. Johnston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. 21(13), 2492-2499 (2003).
19. Cortes J, Albitar M, Thomas D et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101(5), 1692-1697 (2003).
20. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor α and epidermal growth factor in human pancreatic cancer. J. Pathol. 163(2), 111-116 (1991).
21. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth fictor α. J. Clin. Invest. 90(4), 1352-1360 (1992).
22. Li J, Kleeff J, Giese N, Büchler MW, Korc M, Friess H. Gefitinib ('Iressi', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int. J. Oncol. 25(1), 203-210 (2004).
23. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin. Oncol. 25(15), 1960-1966 (2007).
24. Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J. Clin. Oncol. 25(Suppl. Pt 1), 18S LBA4509 (2007).
25. Ignatiadis M, Polyzos A, Stathopoulos GP et al. A multicenter Phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 71(3-4), 159-163 (2006).
26. Ignatiadis M, Polyzos A, Stathopoulos GP et al. A multicenter Phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 71(3-4), 159-163 (2006).
27. Jimeno A, Rubio-Viqueira B, Amador ML et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 65(8), 3003-3010 (2005).
28. Withelm. SM, Carter C, Tang L et al. RAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
29. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
30. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
31. Lee J, Jang KT, Ki CS et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109(8), 1561-1569 (2007).
32. Tzeng CW, Frolov A, Frolova N et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141(4), 464-469 (2007).
33. Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 448(6), 788-796 (2006).
34. Dancer J, Takei H, Ro JY, Lowery-Nordberg M. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization. Oncol. Rep. 18(1), 151-155 (2007).
35. Yamanaka Y, Friess H, Buchler M et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 53(21), 5289-5296 (1993).
36. Safran H, Steinhoff M, Mangray S et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 24(5), 496-499 (2001).
37. Safran H, Iannitti D, Miner T et al. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, Phase I study for advanced pancreaticobiliary cancer. J. Clin. Oncol. 24(Suppl. Pt 1), 18S 4002 (2006).
38. Frolov A, Schuller K, Tzeng CW et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol. Ther. 6(4), 548-554 (2007).
39. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53(4), 549-554 (1988).
40. Viret F, Smedra BT, Esteyries S et al. Genetic predictors of cetuximab response in metastatic colorectal cancer. Presented at: 2008 Gastrointestinal Cancers Symposium. FL, USA, 25-27 January 2008.
41. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal. cancer treated with cetuximab. J. Clin. Oncol, 26(3), 374-379 (2008).
42. Schneider BP, Miller KD. Angiogenesis of breast cancer. J. Clin. Oncol. 23(8), 1782-1790 (2005).
43. Rudin CM, Holmlund J, Fleming GF et al. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7(5), 1214-1220 (2001).
44. Siu LL, Awada A, Takimoto CH et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. 12(1), 144-151 (2006).
45. Hoshino It, Chatani Y, Yamori T et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogenen 18(3), 813-822 (1999).
46. Lorusso PM, Adjei AA, Varterasian M et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23(23), 5281-5293 (2005).
47. Rinehart J, Adjei AA, Lorusso PM et al. Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22(22), 4456-4462 (2004).
48. Korn WM, Mirzoeva OK, Zhang J, Christian C, Knight Z, Shokat K. A specific inhibitor of PI3-kinase isoform p110α and mTOR kills esophageal cancer cells and synergizes with the EGFR inhibitor gefitinib. Presented at: 2008 Gastrointestinal Cancers Symposium. FL, USA, 25-27 January 2008.
49. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61(13), 5090-5101 (2001).
50. Kindler HI, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizurnab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin. Oncol. 25(Suppl. Pt I), 18S 4508 (2007).
51. Wallace JA, Locker G, Nattam S et al. Sorafenib (S) plus genicitabine (G) for advanced pancreatic cancer (PC): a Phase II trial of the University of Chicago Phase II Consortium. J. Clin. Oncol. 25(Suppl. Pt 1), 18S 4608 (2007).
52. Spano J, Chodkiewicz C, Maurel J et al. A randomized Phase II study of axitinib (AG-013736) and gemicitabine versus gemicitabine in advanced pancreatic cancer, preceded by a Phase I component. J. Clin. Oncol. 25(Suppl. Pt 1), 18S 4551 (2007).
53. Kuo T, Fitzgerald A, Kaiser H, Sikic BI, Fisher GA. A Phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 24(Suppl. Pt 1), 18S 4122 (2006).
54. Gharibo MM, Juvidian P, Patrick-Miller L et al. Phase II trial of Gleevec (imatinib mesylate) in patients with metastatic unresectable pancreatic cancer. J. Clin. Oncol. 23(Suppl. Pt 1), 16S 4183 (2005).
55. Yendluri V, Wright JR, Coppola D et al. A small molecule inhibitor of insurin-like growth factor 1 receptor (PQIP) inhibits human pancreatic cancer cell proliferation in vitro and synergizes with erlotinib, Presented at: 2008 Gastrointestinal Cancers Symposium. FL, USA, 25-27 January 2008.
56. Hida K. Hida Y, Shindoh M. Understanding tumor endothehal cell abnormalities to develop ideal antiangiogenic therapies. Cancer Sci. 99(3), 459-466 (2008).